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ABSTRACT
Background. The frequencywithwhich targeted tumorsequenc-
ing results will lead to implemented change in care is un-
clear. Prospective assessment of the feasibility and limitations
of using genomic sequencing is critically important.
Methods. A prospective clinical study was conducted on 100
patients with diverse-histology, rare, or poor-prognosis cancers
to evaluate the clinical actionability of a Clinical Laboratory
Improvement Amendments (CLIA)-certified, comprehensive
genomic profiling assay (FoundationOne), using formalin-fixed,
paraffin-embedded tumors. The primary objectives were to
assess utility, feasibility, and limitations of genomic sequencing
for genomically guided therapy or other clinical purpose in the
setting of a multidisciplinary molecular tumor board.
Results. Of the tumors from the 92 patients with sufficient
tissue,88(96%)hadat leastonegenomicalteration(average3.6,
range 0–10). Commonly altered pathways included p53 (46%),
RAS/RAF/MAPK(rat sarcoma; rapidlyaccelerated fibrosarcoma;
mitogen-activated protein kinase) (45%), receptor tyrosine
kinases/ligand (44%), PI3K/AKT/mTOR (phosphatidylinositol-
4,5-bisphosphate 3-kinase; protein kinase B;mammalian target
ofrapamycin) (35%),transcriptionfactors/regulators (31%),and
cell cycle regulators (30%).Many low frequency but potentially
actionable alterationswere identified indiversehistologies.Use
of comprehensive profiling led to implementable clinical action
in 35% of tumors with genomic alterations, including genomi-
cally guided therapy, diagnostic modification, and trigger for
germline genetic testing.
Conclusion. Use of targeted next-generation sequencing in the
setting of an institutional molecular tumor board led to
implementable clinical action in more than one third of patients
with rare and poor-prognosis cancers. Major barriers to imple-
mentationofgenomicallyguidedtherapywereclinicalstatusofthe
patient and drug access. Early and serial sequencing in the clinical
course and expanded access to genomically guided early-phase
clinical trials and targeted agents may increase actionability.
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Implications for Practice: Identification of key factors that facilitate use of genomic tumor testing results and implementation of
genomically guided therapymay lead to enhanced benefit for patientswith rare ordifficult to treat cancers. Clinical use of a targeted
next-generationsequencingassay in the settingofan institutionalmolecular tumorboard led to implementable clinical action inover
one thirdofpatientswith rareandpoorprognosis cancers.Themajorbarriers to implementationofgenomically guided therapywere
clinical status of the patient and drug access both on trial and off label. Approaches to increase actionability include early and serial
sequencing in the clinical course and expanded access to genomically guided early phase clinical trials and targeted agents.
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INTRODUCTION
Significant advances in sequencing technologies,“synthetic lethal”
strategies to identify targets for loss of function in tumor
suppressors, and pharmacologic innovations have increased both
ourunderstandingof thespectrumofalterationspresent inhuman
cancers anddevelopment of therapeutics [1–5]. Although an ever-
growing spectrum of genomic alterations is now therapeutically
targetable,theclinicalactionabilityofgenomictesting isnotknown.
Widespreadsequencingeffortsdemonstrate thatmost target-
able genomic alterations are not malignancy specific, cannot be
predicted by histology alone, are observed in “target-silent”
tumors, and are useful as predictive or prognostic biomarkers
[2, 6–8]. Furthermore, there is a need to identifymechanisms and
alternative therapeutic strategies after development of drug
resistance [9–13]. Genomic profiling may help circumvent these
inherent clinical challenges by identifying drivers responsible for
survival advantage and drug resistance. It also offers an attractive
approach for rare tumors, given that insufficient numbers of
patients are available to complete clinical trials, andestablishment
of guidelines for best clinical practice remains elusive.
Despite these advantages, the benefits and limitations of
genomic sequencing in clinical practice requires prospective
assessment. Several studies demonstrate that it is possible to
obtain high-quality sequencing data from formalin-fixed,
paraffin-embedded(FFPE) tissues [14,15].However, it remains
unclear how often such genome characterization will actually
lead to implemented, useful clinical interventions.
To understand the feasibility of clinical-grade genomic
sequencing, we implemented a prospective, comprehensive
genomicprofiling protocolwith an institutional,multidisciplinary
moleculartumorboard.Clinicalactionbasedongenomicprofiling
results was possible in 31% of patients in this study. Results
suggestthatthisapproachisfeasible,hasclinicalactionability,and
defines potential barriers to broader implementation.
METHODS
Study Participants
One hundred patients with rare or refractory tumors, evaluated at
the Rutgers Cancer Institute of New Jersey, provided informed
consent for a prospective trial for point-of-care tumor genomic
profiling from April 2013 to December 2013 (supplemental online
Fig. 1). Relevant clinical history, pathology, and genomic profiling
results were reviewed at a formal molecular tumor board (MTB).
Profiling results were discussed in the context of clinical course,
tumor type,mutational frequency, role in cancer biology/behavior,
preplanned therapy, and considerations for genomically guided
therapy. Based on consensus recommendations, those with
actionable alterations were referred for clinical trials, US Food and
Drug Administration (FDA)-approved therapies (on- or off-label),
andgeneticcounseling, ifappropriate,andwerefollowedforclinical
course.TheMTBdidnotproviderecommendationsfornontargeted
therapies,andthetherapeuticapproachwasultimatelythetreating
physician’s choice. The protocol was approved by the Institutional
Review Board of Rutgers RobertWood JohnsonMedical School.
Comprehensive Genomic Profiling
FFPE tissue was sent to Foundation Medicine (Cambridge, MA,
https://www.foundationmedicine.com/) for next-generation se-
quencing using the Clinical Laboratory Improvement Amendments
(CLIA)-certified FoundationOneplatform [15].Targeted sequencing
oftheentirecodingsequencewasdonefor236genesand47introns
of 19 genes involved in fusions at a depth of 3500 to 31,000.
Alterations included point mutations, deletions, amplifications,
duplications, insertions, rearrangements, and splice variants that
were identified as knownor likely pathogenic changes, as reported
by the FoundationOne assay. Variants of unknown significance
(VUS)andsynonymoussingle-nucleotidepolymorphisms(SNPs)are
not included in tables depicting alterations in tumors. Calculations
for “per tumor alterations” excluded VUS and SNPs.
Genomic Profile Clustering
Forunsupervisedclustering,eachofthe92sampleshadatleastone
detected genomic alteration representing only 118 of the possible
236 genes evaluated. A bidirectional, agglomerative hierarchical
clustering with Jaccard’s distancemeasurewas performed. Choice
of distancemeasure wasmotivated by the sparseness of the data
butalsoallowedanalysis to ignorea typeandanumberofgenomic
alterations within a gene or a pathway for a given sample. Data
were treated as binary (0 5 no alteration, 1 5 alteration). The
clustering and visualization were done with a modified version of
“heatmap.2” from the R package “gplots” (R Foundation for
Statistical Computing,Vienna, Austria, https://www.r-project.org/
foundation/) [16]; the corresponding dissimilarity structure was
produced by “dist”with binary distancemeasure.
RESULTS
Genomic Spectrum Reflects Both Intertumoral and
Tumor Type–Specific Commonalities
Fourpediatricand96adultpatientswithrarehistologyorrefractory
cancers underwent tumor genomic profiling for a varied spectrum
ofepithelial andmesenchymal origin tumors (supplemental online
Figs. 1, 2; supplemental online Table 1). At enrollment, 91% of
patients were stage IV and had received a mean of 2.5 prior
therapies. Sixty-fivepercentof patientswerealivewithdisease ata
year ormore after testing,with ameanoverall survival of 129 days
after enrollment. Of the 100 patients enrolled, eight did not have
genomic profiling because of inadequate tissue amount, poor
tissue/DNA quality, or the patient came off study. Ninety-two
patients had successful genomic analysis, with 88 (96%) having
at least one genomic alteration; the average number of alterations
per tumor was 3.6 (range 0–10) (Fig. 1A), with urothelial and
endometrial cancers displaying the highest mutational burden
(supplemental online Fig. 2).
The most commonly altered genes included TP53 (41%),
CDKN2A/B (cyclin-dependent kinase inhibitor 2A/B) (22%), KRAS
(16%), PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase
catalytic subunita) (15%),PTEN (phosphataseandtensinhomolog)
(14%), and BRAF (7%).Therewas also a large set of low-frequency
but actionable changes in tyrosine kinase genes (ALK [anaplastic
lymphoma kinase], KIT [stem cell growth factor receptor], ERBB2
[erb-B2receptortyrosinekinase2],FGFR4 [fibroblastgrowthfactor
receptor 4], KDR [vascular endothelial growth factor receptor 2],
MET [hepatocyte growth factor receptor], NTRK1 [neurotrophic
tyrosine kinase receptor 1], PDGFR [platelet derived growth factor
receptor]) and tumor suppressor genes (BRCA1, BRCA2 [breast
cancer type1, breast cancer type2]).The panel ofgene alterations
was sorted into functional pathways (supplemental online Tables
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2, 3), including the most common: p53 (46%), RAS/RAF/MAPK
(45%),PI3K/AKT/mTOR(35%),transcriptionfactors(31%),cellcycle
(30%), and receptor tyrosine kinases (RTKs) (27%; excluded
fibroblast growth factor [FGF] pathway alterations) (Fig. 2A).
Functional pathways, such as p53, RAS/RAF/MAPK, PI3K/AKT/
mTOR,cellcycle,FGFR/FGF,Wnt(wingless-relatedintegrationsite)/
b-catenin, and DNA repair have profiles in which one or more
alteredgenesareenriched(Fig.2B). Incontrast,transcriptionfactors
and other RTKs have a wider spectrum of affected genes but may
reflect tissue specificity based on tumor type. Furthermore, some
tumor subtypes correlated with a higher probability of harboring
specific alterations (e.g., BRAF-altered papillary thyroid cancers).
As tumor subtype may reflect mutational landscape and this
study profiled diverse tumor types, unsupervised clustering of
Figure 1. Tumorgenomicprofiling consortdiagramandpatientoutcomes. (A):Comprehensivegenomicprofilingof tumors from100patients
with rare or refractory cancers. Time from genomic testing to generation of formal recommendations averaged 3–4 weeks. Clinical action
included enrollment in a therapeutic clinical trial, FDA-approved therapy, off-label use of approved therapy, discontinuation of ineffective
targeted therapy, germlinemutation testing, and diagnostic reclassification. Geneswith alterations for which clinical actionwas implemented
are listed in the respective categories.Twopatients are being screened for participation in clinical trialwith targeted therapy.Twopatientswith
action implemented had targeted therapy prescribed but were then lost to follow-up. (B): Duration of therapy in individual patients before
genomic profiling and with targeted therapy (not significant). Comparisons are for nontargeted therapy before genomic profiling (red) and
durationof targeted therapyaftergenomicprofiling (blue).Greenarrows indicatepatientswithongoing therapy. Lastpatientwasoncombined
therapy with targeted agent, which was discontinued (p) at 5 months for side effects. Patient has ongoing response with monotherapy.
Abbreviation: FDA, U.S. Food and Drug Administration.
www.TheOncologist.com ©AlphaMed Press 2016
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tumorswithat leastonegenomicalterationwasperformedbased
ongene (Fig. 3A) andpathway (Fig. 3B) alterations.Notably, some
tumor subtypes clustered more closely together than tumors of
differingsubtypes.Serialspecimensclusteredmorecloselytoprior
specimens than to similar tumors fromother patients, suggesting
preservation of specific patterns of mutations. Triple-negative
breast cancers clustered closely with ovarian cancers (primarily
high-grade serous), confirming prior data that these tumors may
havesimilarunderlyingbiology.Pathwayclusteringdemonstrated
that, despite diversity in specific mutations, certain pathways are
commonly altered indiverse tumors (e.g.,MAPK, PI3K), and these
paired pathway anomalies are relevant for future design of
multidrug approaches.
Genomic Profiling Alters Clinical Management
The majority of tumors had alterations for which the MTB had
recommended action (Fig. 1A). Of the 88 cases with identified
alterations,87hadclinicallyrelevantalterations.Thecriticalquestion
was, how many of these patients with potentially actionable
genomic alterations identified actually had a change in clinical
management based on sequencing results? Thirty-one patients
had implementation of genomically guided therapy. Another two
Figure 2. Mutational landscape identified in 92 different tumors based on functional pathways. (A): Types of alterations and number of
alterationswerereflectiveof tumorsubtypesprofiled. (B):For9of the10most frequentpathways,the frequencyofgeneswithalterations
within those pathways occurring is depicted. Wnt/b-catenin is not shown but had only two genes represented: APC (adenomatous
polyposis coli) (n5 8) andMSH6 (MutS Homolog 6) (n5 1). Numbers represent the frequency of alterations affecting that gene.
©AlphaMed Press 2016
TheOncologist®
4 Utility of Tumor Molecular Profiling
Published Ahead of Print on August 26, 2016 as 10.1634/theoncologist.2016-0049. 
 by guest on A
pril 19, 2017
http://theoncologist.alpham
edpress.org/
D
ow
nloaded from
 
Figure 3. Hierarchical clustering of tumors with at least one genomic alteration by gene (A) and functional pathway (B). Tumor subtypes are
represented in colored text below heat map and with corresponding boxes above heat map. In (A), box color (rows) within heat map depicts
alteration ingenebytypeofgenomicalteration; in (B), itdepictsalteration ingenes in functionalpathwaybytypeofgenomicalteration.Alteration
key: red, amplification; green,mutation; blue, deletion; purple, rearrangement; black, splice; orange, fusion; white, no alteration.The remaining
colors are multiple alteration subtypes. Numbers in parentheses represent specimen number, and a, b, and c represent serial specimens.
www.TheOncologist.com ©AlphaMed Press 2016
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patients are under screening for genomically guided clinical
trials. Thus, 35% of patients with actionable alterations, and
∼31% of study patients overall, received genomically guided
therapy.
Management decisions based on genomic results (Table 1)
included referral to clinical trials, use of FDA-approved drugs, and
off-label use of targeted therapy when clinical trials were
unavailable (e.g., vemurafenib for BRAF V600E-mutated papillary
thyroid cancer, lapatinib for ERBB2-mutated urothelial cancer,
platinum for BRCA1/2mutations). Examples of clinical responses
included an intestinal carcinoid with FGFR4 mutation with
resolution of bulky mediastinal lymphadenopathy and stability of
retroperitoneal lymphnodeswith sorafenib for 23months; andan
ongoing, 21-month stable response to everolimus in a heavily
pretreated male breast cancer with 8p11 amplification. A patient
withmetastaticpapillaryrenalcellcarcinomawithMETH1094Lhad
objective clinical improvement within 2 months of initiating
crizotinib and is described elsewhere [17].
For patients receiving genomically guided therapy, the mean
number of treatments implemented postsequencing was 1.5,
whereas patients who did not receive targeted therapy despite
target identificationhadameanofonly0.3 treatments (p5 .0001).
Of patients who received targeted therapy, duration on targeted
therapy was 7.6 months (Fig. 1B) compared with 4.2 months for
patients not receiving any targeted therapy (unpublished data,
p 5 .07). However, this includes patients who did not receive
any therapy postsequencing. For those patients who were able to
receive anynontargeted therapy, durationonnontargeted therapy
was6.1months.Thiswasnotstatisticallydifferentfromtheduration
for those who received targeted therapy. One patient was on
combined therapy including a targeted agent, but the latter had to
be discontinued at 5 months because of significant side effects
Figure 3. Continued.
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Table 1. Genomic alterations for which clinical action was implemented.
Tumor type Genomic Alteration Clinical action
Gallbladder BRCA2 Q373* Germline testing
Continued therapy, platinum salt
Recommendation for enrollment in PARP
inhibitor trial
Colon ALK R214H Crizotinib
FGFR1 amplification Regorafenib
Iodine-refractory recurrent papillary thyroid BRAF V600E Vemurafenib: documented response,
clinical improvement lasting several months
Renal cell, papillary MET H1094L MET inhibitor crizotinib with clinical
improvement within 2months and duration
of response 5 months
Urothelial ERBB2 S310F Lapatinib with transient clinical response
Platinum-resistant ductal carcinoma breast,
TNBC
BRCA1 E23fs*17 Etoposide
Krukenberg tumor, likely upper GI source EGFR VIII (epidermal growth factor receptor
variant)
Afatinib
Carcinosarcoma (had initial histologic
diagnosis of GIST)
Lacked KITor PDGFRmutation Discontinued imatinib
BRCA2 T3033fs*12 Patient died suddenly before starting
platinum-based therapy
Pancreatic PIK3CA P104R; FBXW7 R479Q Dual PI3K and mTOR inhibitor
GIST BRAF V600E, Lacked KITor PDGFRmutation Discontinued imatinib; started regorafenib
on recurrence
Colon PIK3CA E545A; PTEN D24fs*17 Dual PI3K and mTOR inhibitor
Endometrial, endometrioid PIK3CA H1047R; PTEN Y336* Everolimus plus exemestane
GIST KIT V559A Regorafenib, sorafenib (prior imatinib,
sunitinib)
Carcinoid FGFR4 D425N Sorafenib
Colon ERBB2 amplification Regorafenib (trastuzumab denied by
insurance)
Phyllodes FGFR1 N546K Pazopanib
Breast cancer FGFR1 amplification Everolimus
Cervical cancer (HPV-associated)a PIK3CAE545K; RET (rearranged during
transfection) V706M
AKT inhibitor
Ductal carcinoma breast, TNBCa BRCA2 N863fs*11, S1982fs*22 PARP inhibitor
Ovarian serous carcinomaa BRCA1Q172fs*62; BRCA2 truncation exon 11 PARP inhibitor
Ovarian serous carcinomaa BRCA1 Q1240* PARP inhibitor; cisplatin
GE junction adenocarcinoma ERBB2 amplification Capecitabine plus lapatinib
Merkel cell MTOR amplification Temsirolimus
Colon KRAS Q61H Regorafenib
GIST KIT L576_P577insPYDL Imatinib
Mesothelioma NF2 (neurofibromin 2) Q456fs*39 Pemetrexed plus temsirolimus
Anaplastic oligodendroglioma PIK3CA H1047R Temozolomide plus everolimus
Colon KRASG12V Regorafenib
Pancreatic STK11 (liver kinase B1) W308fs*8 Pemetrexed
Renal cell, solid tubular/papillary type NF2 splice site 157412T. A AKT inhibitor
Fallopian tube TP53 K132Q Carboplatin
Approved for recommended therapy but
died before administration
Melanoma CCDC91 (coiled-coil domain-containing
protein 91)-BRAF fusion
Trametinib
Urothelial, micropapillary AKT2 amplification, FGFR1 amplification,
RICTOR (rapamycin-insensitive companion of
mammaliantargetofrapamycin)amplification
Temsirolimus
aInitiated targeted therapy on genotype-agnostic trial before profiling results of genomic profiling.
Abbreviations:GE, gastroesophageal;GI, gastrointestinal;GIST, gastrointestinal stromal tumor;HPV, humanpapillomavirus;mTOR,mammalian targetof
rapamycin; PARP, poly(ADP-ribose) polymerase; PI3K, phosphatidylinositol 3-kinase; TNBC, triple-negative breast cancer.
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(Fig. 1B). The patient has ongoing response with nontargeted
monotherapy.Withinthegroupreceivingpostgenomic,nontargeted
therapy, twopatientshada24-monthdurationof this therapy,both
for the treatment of breast cancer. Of these, one had a triple-
negativebreast cancerwithaBRCA2variant, forwhich she received
a platinum-based regimen on clinical trial. The second patient
had a hormonally responsive breast cancer and was receiving
acombinationofanastrozoleplus fulvestrantassecond-linetherapy
in the metastatic setting. Inclusion of these patients substantially
increased thedurationonnontargeted therapy, from4.8months to
6.1months.Therefore,theabilitytodocumentincreaseddurationof
postgenomic therapy comparedwith pregenomic therapy is highly
dependentontumortypeaswellasavailabilityofeffectivestandard
and targeted therapies for specific tumor types. As there are
currently five patients with ongoing treatment with targeted
therapy,themeandurationongenomicallyguidedtherapywouldbe
expected to increase with continued follow-up.
Fifty-threepatientswithpotentiallyactionablegenomicchanges
didnotreceivegenomicallyguidedtherapyprimarilybecauseof lack
of availability of a clinical trial or access to an FDA-approved drug
(n 5 26). An additional 12 patients did not receive treatment
becauseofdeterioratingclinical status.Theremainingpatientswere
ineligible for clinical trials because of comorbid conditions (n5 4),
refused trial participation (n5 1), received nonmatched targeted
drugs (n5 2), or were lost to follow-up (n5 8).
Tumor Genomic Profiling Augments the Cancer
Diagnostic Armamentarium
Several patientswith synchronous, histology-discordant tumorsat
different sites had genomic analysis of all sites. A diagnostically
challenging referral of a synchronous, small bowel tumor and
pelvic mass with unique histologic appearance initially led to
diagnosis of atypical gastrointestinal stromal tumor and ovarian
squamous cell carcinoma, respectively, despite noticeably absent
CD117 expression (Fig. 4). The former represented a high-grade
sarcoma (Figs. 4A–4D), whereas the ovarian mass showed
squamous cell carcinoma (Figs. 4E, 4F). Genomic profiling at both
sites revealed identical alterations in six genes (supplemental
online Table 2). Of six alterations private to the pelvic mass, four
occurred within an amplicon containing the putative driver gene,
CCND1 (cyclin D1). The spectrum of alterations was highly
suggestive of both arising from the sameMu¨llerian precursor,
Figure 4. Genomic profiling aids in the diagnostic analysis of two anatomically distinct tumors from a single patient and ultimately
suggests that tumors arose from the same precursor. Abdominal mass (A–D) shows a high-grade, vimentin-positive sarcoma with
predominantepithelioidappearanceand focalnecrosis. (A,B):hematoxylinandeosin, lowandhighpower, respectively; (C,D): lowpower,
pancytokeratin and vimentin, respectively.The ovarianmass (E, F) shows a poorly differentiated, p40-positive squamous cell carcinoma.
(E): Hematoxylin and eosin, high power. (F): p40, low power. CD117 expression was absent (data not shown).
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displaying both sarcomatous and carcinomatous components
indicative of carcinosarcoma.
An additional patient initially presented with a pancreatic
adenocarcinoma and a synchronous mucinous lung cancer that
wasbelievedtobeasecondunrelatedprimary.Sequencingofboth
tumor specimens showed identical mutations in KRAS and TP53,
again suggesting that these arose from pancreatic adenocarci-
nomaasacommonprecursor.Hadthis informationbeenknownat
diagnosis, the patient may have been spared surgical resection.
Serial Genomic Sequencing Demonstrates
Molecular Evolution
Nine patients had analysis of serial samples at different
time points, with a mean concordance rate of 59% (range,
0%–100%) (supplemental online Table 2). For example, a patient
with metastatic, triple-negative breast cancer had analysis of
threespecimens:primarysiteandbrainmetastasis,bothofwhich
responded to platinum-based chemotherapy, and recurrent,
platinum-resistant cancer that progressed locally (supplemental
online Fig. 3). All specimens from this patient had a core set of
mutations (i.e., BRCA1, known germline), TP53, PIK3CA, and
RUNX1-ATLN (runt-related transcription factor 1; atlastin GTPase
1) fusion. Both the brain metastasis and recurrent tumor had
additional private mutations, suggesting evolution from a com-
monprecursor.Concordancewashigherbetween the twobreast
sites(80%)thanwiththebrainspecimen(50%).Notably,thebrain
metastasis carried an ERBB2 amplificationnot observed in either
breast specimen. No reversion mutation/internal deletion was
noted in BRCA1, despite this knownmechanismof resistance for
poly(ADP-ribose) polymerase and platinum agents [18–20]. A
complex genomic event cannot be ruledout.Thus, serial analysis
of specimens lends insight into tumor evolution and heteroge-
neity. This finding also underscores the importance of analyzing
recurrent metastatic disease that progressed after initial re-
sponse to targeted agents, as potentially actionable targets may
begainedor lost as a result of tumordrift ormolecular evolution,
particularly under selection pressure.
Tumor Sequencing Can Lead to Germline Testing
Genomic sequencing may raise the possibility of germline
mutation testing and is disclosed to participants during
consent. At the MTB, allele frequency and tumor purity are
routinely analyzed when the possibility of germline variants
is raised. In this cohort, previously unknown alterations
in BRCA1/2 were suggested by tumor sequencing in four
patients. In two of these patients with BRCA2 mutations,
further testing showed no evidence of a germline BRCA2
mutation.Twootherpatientswereconfirmedtohavegermline
BRCA1/2mutations and received genetic counseling.
Known alterations in BRCA1 or BRCA2 were confirmed in
four additional caseswithoutevidenceof reversionmutations.
One patient with an activating MET mutation in a papillary
renal cell cancer was also informed of the possibility of
germline mutation. Overall, 10% of tumors from this cohort
exhibited alterations in known cancer susceptibility genes.
Germline testing was recommended based on tumor genomic
profiling and resulted in identifying three individuals with no
prior knowledge of their carrier status.
Tumor genomic profiling without matched normal tissue
has the potential to mistakenly identify germline variants as
somatic tumormutations. Recent reports have suggested that
paired normal/tumor tissue analysis is necessary to eliminate
false-positive calls of germline variants [21, 22]. In this study,
bioinformatics analysis using allele frequency, estimated tumor
purity, and ploidy was used to flag potential germline variants
[23].Of317variants identifiedaspathogenicor likelypathogenic,
29 were flagged as potentially germline (supplemental online
Table 4). Of these, nine variants (e.g., in BRCA1/2) were clearly
identifiedas likelygermlineat theMTBdiscussionand referred to
genetic counseling. Several variants (in RB and TP53) were
eliminated as germline variants on further manual analysis. The
remaining potential germline variants result in a potential false-
positive rate of 5.7% (18 of 317). Analysis of measured allele
frequency, tumor purity, and read depth data by ourMTB allows
identification ofmany of these potential germline variants and is
now routinely done. As such, our MTB recommends genetic
testing for identified potential germline variants when placed in
the context of tumor type, personal history, and family history.
DISCUSSION
Advances in sequencing technologies have led to the ability to
perform clinical-grade, high-depth sequencing of cancer gene
panels to identify clinically relevant tumor genomic alterations.
To determine its clinical actionability, we implemented a
comprehensive genomic profiling protocol with an integrated
institutional, multidisciplinary MTB. We successfully performed
genomic profiling in 92% of rare or poor-prognosis cancers from
patientswhohadexhaustedstandardtherapies,andthistestingled
to actual change in clinical management in 31% of patients.
Importantly, our study also identified recurrent and unsuspected
targetable genomic alterations, consistent with findings by other
groups [24–33]. Somedifferencesbetweenstudiesmay reflect the
spectrumof frequencyof tumor typesaswell asmethodologyand
gene coverage in sequencing panels.
Themain limitation for genomic profiling not leading to clinical
actionwas lackofdrugaccess/availabilityofclinical trials, similar toa
recent report [31]. In some cases, clinical trials were available but
included only a specific tumor subtype, suggesting a need to
significantly increaseaccessthrougheligibility.However,mutational
profiles should be placed in context of the biology of cell/tissue
origin, as exemplified by differences in response to vemurafenib
for BRAF V600E mutant melanoma versus BRAF V600E mutant
colorectal cancer.BRAFV600E remains a genomic target anddriver
in colon cancer; however, to effectively target it in colon cancer,
feedback pathways mediating activation of EGFR and rapid
resistance have to be addressed [26, 34–36].Multigene predictors
of response for targeted therapymay need to be considered [37].
Clinical deterioration in 12% of patients precluded
enrollment on clinical trials, which strongly supports tumor
sequencing earlier in the disease course to maximize the
window of benefit from genomically guided therapy. Our data
show that repeat biopsies upon tumor progression, especially
after therapies that may induce significant selection pressure,
are critical to identify tumor evolution and mechanisms of
resistance [38–44].Thus, there is aneed todogenomicanalysis
“early and often” in the course of treatment.
Although many validated drivers commonly found in
diverse tumor types do not have targeted therapy available
even in early-phase trials, much ongoing drug development
may identify approaches for these alterations that could reach
the clinic in the future and increase eligibility for genomically
www.TheOncologist.com ©AlphaMed Press 2016
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guided therapy. During the course of this study, clinical trials of
IDH inhibitors became available, rendering IDH1/2 (isocitrate
dehydrogenase 1/2) alterations actionable [45]. Moreover,
characterization of novel gene alterations found in individual
tumors is vital, given that specific alterations may confer
differential protein functionality or drug sensitivity, similar to
our novel BRAF fusion identified in a melanoma that may be
resistant to currently available BRAF inhibitors [46].
Target actionability reflects drugavailability in current clinical
trials [31, 32]. A recent report demonstrated that use of an 11- to
50-genehotspotmutationpanel led toan11%rateofenrollment
onto genotype-guided trials, the majority of which were
driven by alterations inPIK3CA/AKT1/PTEN/BRAF [31]. Our study
used a panel targeting a larger range of genomic events and
was integrated with an MTB. This may have led to the higher
actionability rate, although similar targets were identified. Our
studyconfirms thatclinical-gradegenomic analysis is feasible and
can guide clinical decision-making in a subset of patients. Similar
obstacles to implementationofgenomically guided therapywere
identified, including lack of trials, poor clinical status, and lack of
drug access. There is a tradeoff between breadth and depth of
sequencing by current assays [47], and it is not yet clearwhat the
optimal approach and platform is for tumor genomic analysis.
Expectations are that with further advances, it will be possible to
perform more comprehensive sequencing in greater depth.
Improvements in target-drug matching and efficacy of newer
drugs may lead to superior outcomes on targeted therapy.
A critical component of this protocol was implementation
of an integrated, institutional MTB. The MTB brings together a
multidisciplinarygroupofprofessionals todiscussoptimal, genomi-
cally guided clinical options for each patient, a vital point as the
landscape of specific alterations as predictivemarkers continues to
evolve. For example, PIK3CA and PTEN alterations were initially
thought to be potential markers for response to mTOR inhibitors,
but were recently shown not to be the case in some settings [48].
MTB affords clinicians an avenue for better understanding of assay
strengths/limitations, result interpretation/applicability, andclinical
implementation, which may then translate into greater uptake of
genomic testing and improved physician-patient communication
[49, 50]. The systematic multispecialty overview at the MTB also
enhances successful drug acquisition for off-label use of the rapidly
evolving spectrumof targeted agents, especially important for rare
tumors lacking established standards of care.
Although this study highlights the potential of point-of-
care tumor sequencing, theultimatequestion iswhether itwill
lead to improved survival and/or quality of life for cancer
patients. This approach can only lead to improved patient
outcome if partnered with development of novel targeted
agents, expanded trial portfolios, and access to clinical trials.
Further advances in directed use of single or combinatorial
targeted therapywill be needed to translate promise of tumor
genomic characterization into improved patient outcomes.
ACKNOWLEDGMENTS
We thank the patients; Natasha Nicholson and Frances Di
Clemente for administrative support for the Molecular Tumor
Board; and services provided by the Biospecimen Repository
Service and the Office for Human Research Service. This work
was supported by Hugs for Brady,The Val Skinner Foundation,
National Institutes of Health Grant P30CA072720, and a
generous gift to the Genetics Diagnostics to Cancer Treatment
Program of the Rutgers Cancer Institute of New Jersey and
Rutgers University Cell and DNA Repository Infinite Biologics.
AUTHOR CONTRIBUTIONS
Conception/Design: Kim M. Hirshfield, Robert S. DiPaola, Lorna Rodriguez-
Rodriguez, Shridar Ganesan
Provision of studymaterial or patients: KimM. Hirshfield, Mark N. Stein, Susan
Murphy, Hetal Vig, John Glod, Rebecca A. Moss, Lauri Goodell, Howard
Kaufman,ElizabethPoplin, JaniceMehnert,AntoinetteR.Tan, JosephR.Bertino,
Joseph Aisner, Robert S. DiPaola, Lorna Rodriguez-Rodriguez, Shridar Ganesan
Collection and/or assembly of data: Kim M. Hirshfield, Denis Tolkunov, Hua
Zhong, Siraj M. Ali, Mark N. Stein, Susan Murphy, Hetal Vig, David Foran,
Roman Yelensky, Norma A. Palma, James X. Sun, Vincent A. Miller, Philip J.
Stephens, Jeffrey S. Ross, Lorna Rodriguez-Rodriguez, Shridar Ganesan
Data analysis and interpretation: KimM.Hirshfield,DenisTolkunov,HuaZhong,
SirajM.Ali,MarkN. Stein, SusanMurphy,HetalVig, AlexeiVazquez, JohnGlod,
Rebecca A. Moss, Vladimir Belyi, Chang S. Chan, Suzie Chen, Lauri Goodell,
DavidForan,RomanYelensky,NormaA.Palma, JamesX.Sun,VincentA.Miller,
Philip J. Stephens, Jeffrey S. Ross, Howard Kaufman, Elizabeth Poplin, Janice
Mehnert, Antoinette R. Tan, Joseph R. Bertino, Joseph Aisner, Robert S.
DiPaola, Lorna Rodriguez-Rodriguez, Shridar Ganesan
Manuscript writing: KimM. Hirshfield, Denis Tolkunov, Hua Zhong, SirajM. Ali,
Mark N. Stein, SusanMurphy, Hetal Vig, Alexei Vazquez, John Glod, Rebecca
A. Moss, Vladimir Belyi, Chang S. Chan, Suzie Chen, Lauri Goodell, David
Foran, Roman Yelensky, Norma A. Palma, James X. Sun, Vincent A. Miller,
Philip J. Stephens, Jeffrey S. Ross, Howard Kaufman, Elizabeth Poplin, Janice
Mehnert, Antoinette R. Tan, Joseph R. Bertino, Joseph Aisner, Robert S.
DiPaola, Lorna Rodriguez-Rodriguez, Shridar Ganesan
Final approval of manuscript: Kim M. Hirshfield, Denis Tolkunov, Hua Zhong,
SirajM.Ali,MarkN. Stein, SusanMurphy,HetalVig, AlexeiVazquez, JohnGlod,
Rebecca A. Moss, Vladimir Belyi, Chang S. Chan, Suzie Chen, Lauri Goodell,
DavidForan,RomanYelensky,NormaA.Palma, JamesX.Sun,VincentA.Miller,
Philip J. Stephens, Jeffrey S. Ross, Howard Kaufman, Elizabeth Poplin, Janice
Mehnert, Antoinette R. Tan, Joseph R. Bertino, Joseph Aisner, Robert S.
DiPaola, Lorna Rodriguez-Rodriguez, Shridar Ganesan
DISCLOSURES
Siraj M. Ali: FoundationMedicine (E, OI, IP);Mark N. Stein: Jansen,
Astellas,Medivation, Pfizer,Merck,Oncoceutics (RF);RebeccaA.Moss:
Bristol-Myers Squibb (E, OI); Lauri Goodell: Johnson & Johnson (OI);
Roman Yelensky: FoundationMedicine (E, OI); Norma A. Palma:
FoundationMedicine (E); James X. Sun: FoundationMedicine (E, OI);
Vincent A. Miller: FoundationMedicine (E, OI); Philip J. Stephens:
FoundationMedicine (E, OI); Jeffrey S. Ross: FoundationMedicine (RF,
E, OI); Howard Kaufman: Amgen, EMD Serono, Merck, Prometheus,
Sanofi (C/A), Merck (H); Joseph Aisner: Bristol-Myers Squibb, Merck-
Serona (C/A); Shridar Ganesan: Novartis, Inspirata Inc. (C/A), Inspirata
Inc. (OI, IP). The other authors indicated no financial relationships.
(C/A) Consulting/advisory relationship; (RF) Research funding; (E) Employment; (ET) Expert
testimony; (H) Honoraria received; (OI) Ownership interests; (IP) Intellectual property rights/
inventor/patent holder; (SAB) Scientific advisory board
REFERENCES
1. Kandoth C, McLellan MD, Vandin F et al.
Mutational landscape and significance across 12
major cancer types. Nature 2013;502:333–339.
2.Vogelstein B, Papadopoulos N, Velculescu VE
et al. Cancer genome landscapes. Science 2013;339:
1546–1558.
3.McArthur GA, Chapman PB, Robert C et al. Safety
and efficacy of vemurafenib in BRAF(V600E) and BRAF
(V600K) mutation-positive melanoma (BRIM-3): Ex-
tended follow-upof aphase3, randomised, open-label
study. Lancet Oncol 2014;15:323–332.
4. Shaw AT, Kim DW, Nakagawa K et al. Crizotinib
versus chemotherapy in advancedALK-positive lung
cancer. N Engl J Med 2013;368:2385–2394.
5.Tutt A, Robson M, Garber JE et al. Oral poly(ADP-
ribose) polymerase inhibitor olaparib in patients with
BRCA1orBRCA2mutationsandadvancedbreastcancer:
A proof-of-concept trial. Lancet 2010;376:235–244.
6. RomondEH,PerezEA,Bryant J etal.Trastuzumab
plus adjuvant chemotherapy for operable HER2-
positive breast cancer. N Engl J Med 2005;353:
1673–1684.
7. Liu P, Morrison C,Wang L et al. Identification of
somaticmutations innon-small cell lung carcinomas
©AlphaMed Press 2016
TheOncologist®
10 Utility of Tumor Molecular Profiling
Published Ahead of Print on August 26, 2016 as 10.1634/theoncologist.2016-0049. 
 by guest on A
pril 19, 2017
http://theoncologist.alpham
edpress.org/
D
ow
nloaded from
 
using whole-exome sequencing. Carcinogenesis
2012;33:1270–1276.
8. Shah SP, Roth A, Goya R et al. The clonal and
mutational evolution spectrum of primary triple-
negativebreast cancers.Nature 2012;486:395–399.
9. Barrett MT, Lenkiewicz E, Evers L et al. Clonal
evolution and therapeutic resistance in solid
tumors. Front Pharmacol 2013;4:2.
10. Zhang S, Huang WC, Li P et al. Combating
trastuzumab resistanceby targeting SRC, a common
node downstream of multiple resistance pathways.
Nat Med 2011;17:461–469.
11. Shi H, Moriceau G, Kong X et al. Melanoma
whole-exome sequencing identifies (V600E)B-RAF
amplification-mediated acquired B-RAF inhibitor
resistance. Nat Commun 2012;3:724.
12. CeperoV, Sierra JR, CorsoSetal.METandKRAS
gene amplification mediates acquired resistance to
MET tyrosine kinase inhibitors. Cancer Res 2010;70:
7580–7590.
13. Doebele RC, Pilling AB, Aisner DL et al.
Mechanisms of resistance to crizotinib in patients
with ALK gene rearranged non-small cell lung
cancer. Clin Cancer Res 2012;18:1472–1482.
14.Wagle N, Berger MF, Davis MJ et al. High-
throughput detection of actionable genomic alter-
ations in clinical tumor samples by targeted,
massively parallel sequencing. Cancer Discov 2012;
2:82–93.
15. Frampton GM, Fichtenholtz A, Otto GA et al.
Development and validation of a clinical cancer
genomic profiling test based on massively
parallel DNA sequencing. Nat Biotechnol 2013;
31:1023–1031.
16.WarnesGR. gplots: Various R Programming Tools
for Plotting Data. Available at https://cran.r-project.
org/web/packages/gplots/index.html. Accessed July
25, 2016.
17. Stein MN, Hirshfield KM, Zhong H et al.
Response to crizotinib in a patient with MET-
mutant papillary renal cell cancer after progression
on tivantinib. Eur Urol 2015;67:353–354.
18. Sakai W, Swisher EM, Karlan BY et al. Second-
ary mutations as a mechanism of cisplatin re-
sistance in BRCA2-mutated cancers. Nature 2008;
451:1116–1120.
19. Sakai W, Swisher EM, Jacquemont C et al.
Functional restoration of BRCA2 protein by second-
ary BRCA2 mutations in BRCA2-mutated ovarian
carcinoma. Cancer Res 2009;69:6381–6386.
20. Borst P, Rottenberg S, Jonkers J. How do real
tumors become resistant to cisplatin? Cell Cycle
2008;7:1353–1359.
21. Jones S, Anagnostou V, Lytle K et al. Personal-
ized genomic analyses for cancer mutation discov-
ery and interpretation. Sci Transl Med 2015;7:
283ra53.
22. Cheng DT, Mitchell TN, Zehir A et al. Memorial
Sloan Kettering-Integrated Mutation Profiling of
Actionable Cancer Targets (MSK-IMPACT): A hybrid-
ization capture-based next-generation sequencing
clinical assay for solid tumor molecular oncology. J
Mol Diagn 2015;17:251–264.
23. Sun J, Frampton G, Wang K et al. A computa-
tionalmethodforsomaticvs. germ-linevariant status
determination from targeted next-generation se-
quencing of clinical cancer specimens without a
matched normal control. Cancer Res 2014;74(suppl
19):1893a.
24. Andre´ F, Bachelot T, Commo F et al. Compar-
ative genomic hybridisation array and DNA se-
quencing to direct treatment of metastatic breast
cancer: A multicentre, prospective trial (SAFIR01/
UNICANCER). Lancet Oncol 2014;15:267–274.
25. Kris MG, Johnson BE, Berry LD et al. Using
multiplexed assays of oncogenic drivers in lung
cancers to select targeted drugs. JAMA 2014;311:
1998–2006.
26. Lipson D, Capelletti M, Yelensky R et al.
Identification of new ALK and RET gene fusions
from colorectal and lung cancer biopsies. Nat Med
2012;18:382–384.
27. Herter-Sprie GS, Greulich H,Wong KK. Activat-
ing mutations in ERBB2 and their impact on
diagnostics and treatment. Front Oncol 2013;3:86.
28. Balschun K, Haag J, Wenke AK et al. KRAS,
NRAS, PIK3CA exon 20, and BRAF genotypes in
synchronous and metachronous primary colorectal
cancers: Diagnostic and therapeutic implications.
J Mol Diagn 2011;13:436–445.
29. Lechner M, Frampton GM, Fenton T et al.
Targeted next-generation sequencing of head and
neck squamous cell carcinoma identifies novel
genetic alterations in HPV1 and HPV- tumors.
Genome Med 2013;5:49.
30. Hirshfield KM, Aisner J, Ali SM et al. Targeted
treatment of RAI-resistant metastatic thyroid can-
cer postcomprehensive genomic profiling. J Clin
Oncol 2014;32(suppl):e22070a.
31.Meric-Bernstam F, Brusco L, Shaw K et al.
Feasibilityof large-scalegenomic testing to facilitate
enrollment ontogenomicallymatchedclinical trials.
J Clin Oncol 2015;33:2753–2762.
32. Boland GM, Piha-Paul SA, Subbiah V et al.
Clinical next generation sequencing to identify
actionable aberrations in a phase I program.
Oncotarget 2015;6:20099–20110.
33. Beltran H, Eng K, Mosquera JM et al. Whole-
exome sequencing of metastatic cancer and bio-
markers of treatment response. JAMA Oncol 2015;
1:466–474.
34. Prahallad A, Sun C, Huang S et al. Unrespon-
siveness of colon cancer to BRAF(V600E) inhibition
through feedback activation of EGFR. Nature 2012;
483:100–103.
35. Corcoran RB, Ebi H, Turke AB et al. EGFR-
mediated re-activation of MAPK signaling contrib-
utes to insensitivity of BRAF mutant colorectal
cancers to RAF inhibition with vemurafenib. Cancer
Discov 2012;2:227–235.
36.Yaeger R, Cercek A, O’Reilly EM et al. Pilot trial
of combined BRAF and EGFR inhibition in BRAF-
mutant metastatic colorectal cancer patients. Clin
Cancer Res 2015;21:1313–1320.
37.Tabchy A, Eltonsy N, Housman DE et al.
Systematic identification of combinatorial drivers
and targets in cancer cell lines. PLoS One 2013;8:
e60339.
38. Johnson BE, Mazor T, Hong C et al. Mutational
analysis reveals the origin and therapy-driven
evolution of recurrent glioma. Science 2014;343:
189–193.
39. Balko JM,Giltnane JM,Wang K et al.Molecular
profiling of the residual disease of triple-negative
breast cancers after neoadjuvant chemotherapy
identifies actionable therapeutic targets. Cancer
Discov 2014;4:232–245.
40.Meric-Bernstam F, Frampton GM, Ferrer-
Lozano J et al. Concordance of genomic alterations
between primary and recurrent breast cancer. Mol
Cancer Ther 2014;13:1382–1389.
41. Axelrod M, Gordon VL, Conaway M et al.
Combinatorial drug screening identifies compensatory
pathway interactions and adaptive resistance mecha-
nisms. Oncotarget 2013;4:622–635.
42. Abel EV, Basile KJ, Kugel CH 3rd et al.
Melanoma adapts to RAF/MEK inhibitors through
FOXD3-mediated upregulation of ERBB3. J Clin
Invest 2013;123:2155–2168.
43.Vignot S, Frampton GM, Soria JC et al. Next-
generation sequencing reveals high concordance of
recurrent somatic alterations between primary
tumor and metastases from patients with non-
small-cell lung cancer. J Clin Oncol 2013;31:
2167–2172.
44. Peeters M, Oliner KS, Parker A et al. Massively
parallel tumor multigene sequencing to evaluate
response to panitumumab in a randomized phase III
study of metastatic colorectal cancer. Clin Cancer
Res 2013;19:1902–1912.
45. Stein E, Tallman M, Pollyea DA et al. Clinical
safety and activity in a phase I trial of AG-221, a first
in class, potent inhibitor of the IDH2-mutant
protein, in patients with IDH2 mutant positive
advanced hematologic malignancies. Cancer Res
2014;74(suppl 19):CT103a.
46. Sievert AJ, Lang SS, Boucher KL et al. Paradox-
ical activation and RAF inhibitor resistance of BRAF
protein kinase fusions characterizing pediatric
astrocytomas. Proc Natl Acad Sci USA 2013;110:
5957–5962.
47. Sims D, Sudbery I, Ilott NE et al. Sequencing
depth and coverage: Key considerations in genomic
analyses. Nat Rev Genet 2014;15:121–132.
48. Janku F, Hong DS, Fu S et al. Assessing PIK3CA
and PTEN in early-phase trials with PI3K/AKT/mTOR
inhibitors. Cell Reports 2014;6:377–387.
49.Miller FA, Hayeems RZ, Bytautas JP et al.
Testing personalized medicine: Patient and physi-
cian expectations of next-generation genomic
sequencing in late-stage cancer care. Eur J Hum
Genet 2014;22:391–395.
50. Gray SW, Hicks-Courant K, Cronin A et al.
Physicians’ attitudes about multiplex tumor geno-
mic testing. J Clin Oncol 2014;32:1317–1323.
See http://www.TheOncologist.com for supplemental material available online.
www.TheOncologist.com ©AlphaMed Press 2016
Hirshfield, Tolkunov, Zhong et al. 11
Published Ahead of Print on August 26, 2016 as 10.1634/theoncologist.2016-0049. 
 by guest on A
pril 19, 2017
http://theoncologist.alpham
edpress.org/
D
ow
nloaded from
 
